Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mk-8033. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 20/20 | 1.00 |
| ▸ | MST1R known ✓ | Q04912 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-8033 SCHEMBL29395425 | 1.00 | MET (1.00) | METCYP3A4CYP2D6CYP2C9FECH | |
| Mk-8033 SCHEMBL10322477 | 0.99 | MET (0.98) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL399288 | 0.91 | MET (0.84) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL400331 | 0.90 | MET (1.00) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL399315 | 0.90 | MET (0.82) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL399926 | 0.90 | MET (1.00) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL398620 | 0.89 | MET (0.81) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL398780 | 0.89 | MET (0.81) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL400903 | 0.89 | MET (0.79) | METCYP3A4CYP2D6CYP2C9FECH | |
| SCHEMBL400034 | 0.89 | MET (0.79) | METCYP3A4CYP2D6CYP2C9FECH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2482803-B1 | FORMULATIONS FOR C-MET KINASE INHIBITORS | MERCK SHARP & DOHME UK LTD (GB) | 2021-12-22 | — | — | EP | claimed |
| US-9238571-B2 | Formulations for c-Met kinase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2016-01-19 | — | — | US | claimed |
| EP-2049494-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | claimed |
| US-8674105-B2 | Crystalline hydrochloride salts of c-Met kinase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2014-03-18 | — | — | US | claimed |
| EP-2482821-A1 | CRYSTALLINE HYDROCHLORIDE SALTS OF C-MET KINASE INHIBITORS | Schering Corporation (US) | 2012-08-08 | — | — | EP | claimed |
| EP-2482803-A1 | FORMULATIONS FOR C-MET KINASE INHIBITORS | Merck Sharp & Dohme Limited (GB) | 2012-08-08 | — | — | EP | claimed |
| US-20120184744-A1 | CRYSTALLINE HYDROCHLORIDE SALTS OF C-MET KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-19 | — | — | US | claimed |
| US-8222269-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-17 | — | — | US | claimed |
| US-8101603-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-01-24 | — | — | US | claimed |
| WO-2011041157-A1 | CRYSTALLINE HYDROCHLORIDE SALTS OF C-MET KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-07 | — | — | WO | claimed |
| WO-2011039527-A1 | FORMULATIONS FOR C-MET KINASE INHIBITORS | MERCK SHARP & DOHME LTD (GB) | 2011-04-07 | — | — | WO | claimed |
| US-20090203684-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-08-13 | — | — | US | claimed |
| US-20090012076-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-01-08 | — | — | US | claimed |
| EP-4416306-A1 | METHODS FOR DETERMINING THE LIKELIHOOD OF A MALIGNANT DISEASE RESPONDING TO TREATMENT WITH A PHARMACEUTICAL INHIBITOR | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023062115-A1 | METHODS FOR DETERMINING THE LIKELIHOOD OF A MALIGNANT DISEASE RESPONDING TO TREATMENT WITH A PHARMACEUTICAL INHIBITOR | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2023-04-20 | — | — | WO | disclosed |
| US-20220184090-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | NOVARTIS AG (CH) | 2022-06-16 | — | — | US | disclosed |
| US-20090012076-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-01-08 | — | — | US | disclosed |
| US-20090012076-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-01-08 | — | — | US | disclosed |
| US-20090012076-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-01-08 | — | — | US | disclosed |
| WO-2008008310-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184090-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | EGFR, ERBB2, ERBB3 | MET 4/4885MST1R 418/4885CYP3A4 2744/4885 |
| US-20090012076-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, MET | MET 3/4885MST1R 181/4885CYP3A4 3774/4885 |
| US-20090203684-A1 | Tyrosine kinase inhibitors | ABL1, MET, ERBB2 | MET 2/4885MST1R 204/4885CYP3A4 3658/4885 |
| US-20120184744-A1 | CRYSTALLINE HYDROCHLORIDE SALTS OF C-MET KINASE INHIBITORS | MET, RET, ALK | MET 1/4885MST1R 331/4885CYP3A4 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.